TiGenix NV , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office has issued European Patent EP2292736 relating to an adipose-derived stem cell composition. The patent is entitled "Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue" .
http://ift.tt/1ASxf7L
http://ift.tt/1ASxf7L
No comments:
Post a Comment